Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Idorsia Ltd (IDRSF) reports significant growth in QUVIVIQ sales and successful debt restructuring, while navigating financial ...

In a report released on February 26, Justine Telliez from Kepler Capital maintained a Hold rating on Idorsia Ltd (IDIA – Research Report), ...

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

Good day and thank you for standing by. Welcome to the Idorsia Full Year 2024 Financial Results Webcast. At this time, all participants are in listen-only mode. After the speakers' presentation ...

In a report released on February 12, Justine Telliez from Kepler Capital maintained a Hold rating on Idorsia Ltd (IDIA – Research Report), with a price target of CHF2.20. Leverage the power of ...

Idorsia Ltd is reaching out for more - we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms ...

Idorsia Ltd (SIX: IDIA) today announced that it has published the agenda items for the bondholder meeting for holders of its outstanding convertible bond (ISIN: CH0426820350) (the Bonds or CB 2025 ...

Ad hoc announcement pursuant to Art. 53 LR More than the required two-thirds majority of bondholders reach agreement on the main terms for the restructuring of Idorsia’s outstanding convertible bond d ...

Idorsia Ltd (SIX: IDIA) today announced that it has published an invitation to a bondholder meeting for holders of its outstanding convertible bond (ISIN: CH0426820350) (the Bonds or CB 2025 ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Idorsia Ltd (SIX: IDIA) today announced that it has reached an agreement with Viatris Inc. (NASDAQ: VTRS) to update the terms of the global development and commercialization collaboration for ...